Rigel Pharmaceuticals, Inc. (RIGL) Financial Statements

Comprehensive financial analysis for RIGL including key ratios, revenue trends, profitability metrics, and analyst recommendations. Get detailed RIGL financial performance analysis and investment insights.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio (TTM):7.38

Forward P/E:12.10

EPS (TTM):$5.43

Enterprise Value:$661.37M

Profitability Ratios

Profit Margin:36.51%

Return on Equity:376.09%

Return on Assets:39.01%

Operating Margin:60.09%

Financial Health

Current Ratio:2.02

Quick Ratio:1.71

Debt to Equity:74.50

Beta (5Y):1.21

Revenue and Profit Trends

Growth Metrics

Revenue Growth

176.00%

Revenue Per Share

$15.11

Performance Metrics

Profit Margin Trend

36.51%

Return on Equity

376.09%

Return on Assets

39.01%

Analyst Insights

Price Targets

Average Target

$38.33

High Target

$67.00

Low Target

$23.00

Analyst Recommendations

Recommendation

Buy

Analyst Coverage

6 Analysts

Upside Potential

-4.3%